000 | 01910 a2200469 4500 | ||
---|---|---|---|
005 | 20250515110812.0 | ||
264 | 0 | _c20080603 | |
008 | 200806s 0 0 eng d | ||
022 | _a1078-0432 | ||
024 | 7 |
_a10.1158/1078-0432.CCR-07-4097 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aFox, Elizabeth | |
245 | 0 | 0 |
_aA phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. _h[electronic resource] |
260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cFeb 2008 |
||
300 |
_a1111-5 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
650 | 0 | 4 | _aChild |
650 | 0 | 4 | _aChild, Preschool |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMaximum Tolerated Dose |
650 | 0 | 4 |
_aNeoplasm Recurrence, Local _xdrug therapy |
650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
650 | 0 | 4 |
_aSulfonamides _xadministration & dosage |
650 | 0 | 4 |
_aTubulin Modulators _xadministration & dosage |
700 | 1 | _aMaris, John M | |
700 | 1 | _aWidemann, Brigitte C | |
700 | 1 | _aGoodspeed, Wendy | |
700 | 1 | _aGoodwin, Anne | |
700 | 1 | _aKromplewski, Marie | |
700 | 1 | _aFouts, Molly E | |
700 | 1 | _aMedina, Diane | |
700 | 1 | _aCohn, Susan L | |
700 | 1 | _aKrivoshik, Andrew | |
700 | 1 | _aHagey, Anne E | |
700 | 1 | _aAdamson, Peter C | |
700 | 1 | _aBalis, Frank M | |
773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 14 _gno. 4 _gp. 1111-5 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-07-4097 _zAvailable from publisher's website |
999 |
_c17786022 _d17786022 |